We are excited to announce that Cmed has today joined the AIXIAL Group and ALTEN Group. ALTEN is a world leader in Engineering and Technology consulting with 37,000 engineers and scientists located in more than 30 countries throughout the world. It serves customers in a range of industries and has a depth and breadth of experience and expertise across life sciences, software development and artificial intelligence. AIXIAL Group, an ALTEN company, is a CRO renowned for its flexible and functional resourcing.
At encapsia, we are pleased to be working with a like-minded partner in endpoint. With both organizations focused on simplifying the user experience and management of complex trials through technology, it was a natural step to integrate our two state-of-the-art technology systems to drive innovation and generate significant efficiencies in the clinical trial space. With encapsia, site users no longer need to use a separate IRT system – they do all their work in encapsia.
Each year we eagerly await the kick-off to the conference season with Arena’s Outsourcing in Clinical Trials (OCT) West Coast event. The conference brings together biotech and pharmaceutical clinical operations, outsourcing and procurement management, while showcasing innovations and technological advancements in the clinical trial space. This year was no exception and although the event was virtual, OCT West Coast managed to gather over 800 clinical trial professionals, looking to meet their peers and share insights into how we can conduct clinical trials of the future.
Running a rare disease study includes many challenges. It’s a more difficult patient population to access which leads to difficulties in patient recruitment, fewer medical experts available, navigation through often complex regulations, as well as potentially complex study designs. This small population makes these studies expensive as you need more sites, maybe across more countries with more time in conduct to achieve your recruitment targets – resulting in costly set-up, management and monitoring of your study.
Sponsors agree the coronavirus pandemic exposed shortcomings of existing processes in clinical trials
Modern technologies support agile processes for clinical trials 95% of attendees to our webinar this week agreed with the central message that processes and supporting technologies commonly used in clinical trials are outdated, and furthermore they contributed to the huge disruption of clinical trials caused by the COVID-19 pandemic. Systems and methods for data collection, monitoring, review and analysis have evolved in a piecemeal fashion, and whether well suited or not, are normally “bolted together”.
This was one of several deliberately thought-provoking questions raised in our webinar last month, “COVID-19: The catalyst for long overdue change in clinical trial technologies and processes”. In the first session, Gurpal Ahluwalia (Partner at BDO Life Sciences) assessed the disruptive impact of COVID-19 on clinical trials and the reasons why the industry has found itself in such difficulty. Cmed CEO, David Connelly, then shared some further perspective on the shortcomings of existing technologies and processes and suggested these contributed to the degree of disruption caused by the pandemic.